Skip to Main Content
An official website of the United States government

Approved Projects

Here you can browse the complete list of projects on CDAS whose requests for data/biospecimens were approved.

Filter results of approved projects table below

Showing Most Recent
1-20 of 2716
Approved Projects
Name Principal Investigator Institution Study Date Approved Project ID
AEGIS — AI-Enabled Genomic and Integrated Stratification for Multi-Cancer Risk: Deep-Learning Development and Internal Validation in the PLCO Cohort Aneel Paulus West Eastern Health PLCO Jul 14, 2026 PLCO-2064
Development of generalizable pathology foundation models for cancer prognosis using PLCO whole slide images Marvin Lerousseau Spotlight Medical, SAS PLCO Jul 14, 2026 PLCOI-2060
NeuroAI-PLCO Images: Longitudinal Risk Stratification Using PLCO Imaging and Structured Data Richard Tran Trove-AI PLCO Jul 14, 2026 PLCOI-2056
Developing Quantitative AI-histologic Signatures Associated with Prognosis and Treatment Benefit Across Cancer Types in the PLCO Trial Haochen Zhang Valar Labs PLCO Jul 14, 2026 PLCOI-2054
NeuroAI-Lung: Longitudinal Risk Stratification Using NLST Low-Dose CT Data Richard Tran Trove-AI NLST Jul 14, 2026 NLST-1519
PLCO Germline Materials for Integrated Whole-Genome Discovery of Lung Cancer Susceptibility with the Sherlock-Lung Study Maria Teresa Landi National Cancer Institute, National Institutes of Health PLCO Jul 8, 2026 2026-0117
Repurposing: Efficient use of excess PLCO biospecimens to investigate DNA methylation patterns and cardiovascular disease mortality risk Jason Wong National Heart Lung and Blood Institute PLCO Jun 25, 2026 2026-8083
ABO Blood Type and Secretor Status as Determinants of Oral Microbiome Composition and Cancer Risk: Evidence from the PLCO Cohort Emily Vogtmann National Cancer Institute PLCO Jun 18, 2026 PLCO-2058
Longitudinal study of socioeconomic factors, stress-related biomarkers, and aggressive prostate cancer Kathryn Barry University of Maryland, Baltimore PLCO Jun 17, 2026 2026-0158
Multi-population study of serum protein biomarkers and prostate cancer risk Sonja Berndt National Cancer Institute PLCO Jun 17, 2026 2026-0154
Leveraging antibody responses against transposable elements as a novel immune therapy for ovarian cancer Rebecca Lynch The George Washington University School of Medicine and Health Sciences PLCO Jun 17, 2026 2026-0096
Exosome-based microRNA Biomarkers for Non-invasive and Early Detection of Colorectal Cancer and Advanced Adenomas Ajay Goel City of Hope PLCO Jun 16, 2026 2025-0016
Efficient Design and Analysis of Two-Phase Biomarker Studies Li Cheung National Cancer Institute PLCO Jun 8, 2026 PLCO-2053
PLCO Digital Pathology Whole-Slide Images for Prostate, Lung, and Ovarian Cancer AI Modeling and Validation Yuming Jiang Wake Forest University Health Sciences PLCO Jun 8, 2026 PLCOI-2052
Impact of deep learning lung cancer risk models on clinical decisions with blood-based diagnostics Michael Kammer Biodesix, inc NLST Jun 8, 2026 NLST-1515
Designing a Targeted Lung Cancer (LC) Screening Trial in the U.S. Screening-Ineligible Population Using Synthetic Cohorts and Natural History Modelling Thomas Trikalinos Brown University PLCO Jun 1, 2026 PLCO-2047
Scalable and Reproducible Deep Learning Strategies for Lung Cancer Screening Imaging Stefano Diciotti Alma Mater Studiorum - Department DEI NLST Jun 1, 2026 NLST-1514
Deep Learning to Improve Screening of Interstitial Lung Diseases (NLST-1505 continued) Charles Hatt IMBIO, a 4D Medical Company NLST Jun 1, 2026 NLST-1506
Heterogeneity of screening effects (Original Project: NLST-1098) Hormuzd Katki American Cancer Society NLST May 29, 2026 NLST-1509
Behavioral effects of screening offers Ethan Lieber University of Notre Dame du Lac PLCO May 29, 2026 PLCO-2044